Insider Selling: Equillium (NASDAQ:EQ) COO Sells $150,000.00 in Stock

Equillium, Inc. (NASDAQ:EQ) COO Christine Zedelmayer sold 100,000 shares of the stock in a transaction that occurred on Tuesday, December 23rd. The stock was sold at an average price of $1.50, for a total transaction of $150,000.00. Following the completion of the transaction, the chief operating officer owned 91,444 shares in the company, valued at approximately $137,166. This trade represents a 52.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Christine Zedelmayer also recently made the following trade(s):

• On Monday, December 15th, Christine Zedelmayer sold 11,900 shares of Equillium stock. The shares were sold at an average price of $1.31, for a total transaction of $15,589.00.
• On Friday, December 12th, Christine Zedelmayer sold 23,804 shares of Equillium stock. The shares were sold at an average price of $1.34, for a total transaction of $31,897.36.
• On Tuesday, November 25th, Christine Zedelmayer sold 8,098 shares of Equillium stock. The stock was sold at an average price of $0.95, for a total transaction of $7,693.10.

Equillium Trading Up 20.4%

Shares of NASDAQ:EQ opened at $1.63 on Friday. The company has a market capitalization of $98.95 million, a price-to-earnings ratio of -2.62 and a beta of 1.92. Equillium, Inc. has a 12-month low of $0.27 and a 12-month high of $2.35. The business has a 50-day moving average price of $1.16 and a 200 day moving average price of $1.04.

Equillium (NASDAQ:EQ) last announced its earnings results on Thursday, November 13th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.08. As a group, equities research analysts predict that Equillium, Inc. will post 0.14 earnings per share for the current fiscal year.

Institutional Trading of Equillium

Large investors have recently modified their holdings of the stock. Virtu Financial LLC raised its stake in shares of Equillium by 133.4% in the third quarter. Virtu Financial LLC now owns 23,779 shares of the company’s stock valued at $34,000 after acquiring an additional 13,591 shares in the last quarter. Millennium Management LLC purchased a new stake in Equillium during the 3rd quarter worth about $35,000. Persistent Asset Partners Ltd acquired a new stake in Equillium in the 3rd quarter valued at about $99,000. Boothbay Fund Management LLC purchased a new position in shares of Equillium in the 3rd quarter valued at about $174,000. Finally, Schonfeld Strategic Advisors LLC purchased a new position in shares of Equillium in the 3rd quarter valued at about $178,000. Hedge funds and other institutional investors own 27.05% of the company’s stock.

Wall Street Analysts Forecast Growth

EQ has been the subject of several research analyst reports. Wall Street Zen upgraded Equillium from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Equillium in a research note on Monday. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Reduce” and a consensus target price of $1.00.

Equillium Company Profile

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.